http://rdf.ncbi.nlm.nih.gov/pubchem/patent/KR-102209537-B1
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-505 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/Y02A50-30 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-395 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K48-00 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K48-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-395 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-00 |
| filingDate | 2018-08-27-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2021-01-29-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2021-01-29-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | KR-102209537-B1 |
| titleOfInvention | Composition for treating metastic cancer |
| abstract | The present invention relates to a composition for the treatment of metastatic cancer having a strong inhibitory effect on metastasis and invasiveness of metastatic cancer cells through inhibition of the expression and action of PLK1, and PLK1 containing a specific point mutation or inhibition of the expression and action of PLK1 of the present invention It has been newly revealed that the protein has a strong inhibitory effect on the treatment or prevention of cancer, particularly on metastasis or invasion of cancer cells through inhibition of the expression and action of PLK1, and can be widely used in the treatment of metastatic cancer. |
| priorityDate | 2017-11-27-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 419.